Biogen Idec has confirmed
the TGA approval of Tecfidera
(dimethyl fumarate), which is a new
oral treatment for patients with
relapsing multiple sclerosis.
Tecfidera has also been
recommended for PBS listing, and
Biogen Idec says it will introduce
a Product Familiarisation Program
for the medication which will be
available to suitable MS patients via
neurologists in Australia.
Tecfidera has been shown to
reduce important measures of
disease activity including relapses
and development of brain lesions .
It’s also been proven to slow
disability progression over time,
while showing a favourable safety
and tolerability profile.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Sep 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.